Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

River blindness vaccine set for cattle trials
The vaccine is being developed by biotechnology company Vaxine Pty.

Vaccine uses unique sugar-based adjuvant

Scientists in Australia are developing a vaccine that could prevent millions of cases of river blindness.

According to The Lead South Australia, the vaccine is being developed by biotechnology company Vaxine Pty and is set for trials in 2017.

Vaxine scientific director Nikolai Petrovsky explained that the vaccine uses a two-pronged approach to effectively prevent the disease.


“First we’re looking to vaccinate the cattle, which are a breeding ground for the parasite,” he said. 
“Then, the other side of this is to immunise the children so if they come in contact with the parasite it blocks the infection.


“Our technology is a bit like melding a turbocharger to the engine and in this case makes the vaccine dramatically more powerful.”

According to the World Health Organisation, river blindness affects some 17 million people globally. Ninety per cent of these cases occur in west and central Africa.


Caused by the parasitic worm Onchocerca volvulus, river blindness is spread to humans and cattle by blackflies that breed in rivers. Symptoms of the disease include severe itching, disfigurative skin conditions and visual impairment - including permanent blindness.

Professor Petrovsky said the new vaccine uses a unique sugar-based adjuvant, which is safer than existing methods.

“We offer a new alternative that is not only potentially safer because it is a sugar instead of a metal/salt with high toxicity,” he told The Lead. 

“Our adjuvant also works for a lot of vaccines that wouldn’t work with aluminium. The ones that tried to create an onchocerciasis vaccine didn’t take but ours actually works.”

The vaccine was developed in association with Thomas Jefferson University and the New York Blood Centre in the United States.

The team have received a grant from the US government and hope to begin tests for the cattle trial in the coming weeks.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.